Geron Valuation
| GERN Stock | USD 2.37 0.02 0.84% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Geron retains a regular Real Value of $2.82 per share. The prevalent price of the firm is $2.37. Our model calculates the value of Geron from evaluating the firm fundamentals such as Return On Asset of -0.3, shares outstanding of 604.5 M, and Return On Equity of -0.69 as well as inspecting its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Geron's price fluctuation is relatively risky at this time. Calculation of the real value of Geron is based on 3 months time horizon. Increasing Geron's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Geron is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Geron Stock. However, Geron's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.37 | Real 2.82 | Hype 2.37 | Naive 2.23 |
The intrinsic value of Geron's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Geron's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Geron helps investors to forecast how Geron stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Geron more accurately as focusing exclusively on Geron's fundamentals will not take into account other important factors: Geron Total Value Analysis
Geron is currently projected to have valuation of 1.19 B with market capitalization of 1.44 B, debt of 85.9 M, and cash on hands of 219.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Geron fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.19 B | 1.44 B | 85.9 M | 219.29 M |
Geron Investor Information
About 82.0% of the company shares are owned by institutional investors. The book value of Geron was currently reported as 0.49. The company recorded a loss per share of 0.32. Geron had not issued any dividends in recent years. The entity had 1058:1000 split on the 22nd of July 2014. Based on the analysis of Geron's profitability, liquidity, and operating efficiency, Geron is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Geron Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Geron has an asset utilization ratio of 0.0601 percent. This suggests that the Company is making $6.01E-4 for each dollar of assets. An increasing asset utilization means that Geron is more efficient with each dollar of assets it utilizes for everyday operations.Geron Ownership Allocation
Geron has a total of 604.5 Million outstanding shares. The majority of Geron outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Geron to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Geron. Please pay attention to any change in the institutional holdings of Geron as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Geron Profitability Analysis
The company reported the previous year's revenue of 237 K. Net Loss for the year was (184.13 M) with loss before overhead, payroll, taxes, and interest of (82.9 M).About Geron Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Geron. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Geron based exclusively on its fundamental and basic technical indicators. By analyzing Geron's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Geron's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Geron. We calculate exposure to Geron's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Geron's related companies.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. The company was incorporated in 1990 and is headquartered in Foster City, California. Geron Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Geron Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 570.6 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Geron. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.